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Abstract: More than 90 % of cancer-related deaths are due to the development of a systemic metastatic disease.
Clearly, much remains to be understood about the biological principles that govern human cancer metastasis,
aiming at the ambitious objective to decrease metastasis-related mortality in patients. For many years, research on
metastasis has been conducted in great part on experimental mouse models, mainly because of the difficulties in
sampling, longitudinal studies, and molecular interrogation of a human metastatic disease. However, recently,
extraordinary advances in microfluidic technologies are allowing the isolation and characterization of human
circulating tumor cells (CTCs) that escaped a primary tumor mass and are in the process of seeding a distant
metastasis. Analysis of human CTCs has now revealed important features of cancer metastasis, such as the high
metastatic potential of CTC-clusters compared to single CTCs, the dynamic expression of epithelial and mesenchymal
markers on CTCs during treatment, and the possibility to culture CTCs from patients for a real-time and individualized
testing of drug susceptibility. Nevertheless, several aspects of CTC biology remain unsolved, such as the characterization
of the stem-like cell population among human CTCs. Here, we focus on describing the latest findings in the CTC field,
and discuss them in the context of cancer stem cell biology. Defining the molecular features of those few metastasis-
initiating, stem-like CTCs holds the exceptional promise to develop metastasis-tailored therapies for patients with
cancer.
Reviewers: This article was reviewed by Elisa Cimetta, Luca Pellegrini and Sirio Dupont (nominated by LP).
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Background
Cancer is the outcome of a complex, multi-step evolu-
tionary process during which normal cells acquire aber-
rant features that enable them to become tumorigenic
and ultimately malignant [1]. Currently, despite remark-
able advances in diagnosis, surgical techniques and anti-
cancer therapies, cancer remains among the leading
causes of death worldwide, with a projected 70 % in-
crease in new cases in the next 20 years according to the
World Health Organization (WHO). It is estimated that,
annually, more than 8 million people die from cancer
worldwide, and more than 90 % of these cancer-related
deaths are due to the formation and progression of a
systemic metastatic disease [2–6]. These numbers reflect
our limited understanding of the key processes that drive
human cancer metastasis. To date, most of our un-
derstanding of the metastatic process derives from
experimental mouse models. These models are well
established, can be genetically manipulated and are ideal
for studying tumorigenic and metastatic properties of
human cancer cell lines, as well as genetically-
engineered endogenous mouse cancer cells. However,
although instructive, conclusions derived from mouse
models need to be validated in human specimens. This
has proven to be extremely challenging mainly because
human metastatic sites are difficult to biopsy, and the
limited material obtained is often highly admixed with
surrounding healthy stromal tissue. On the other hand,
recent breakthrough technological advances that are
emerging, are now enabling the isolation and
characterization of human cancer cells in transit
through the bloodstream, on their way to distant or-
gans, with an outstanding potential to reveal those
fundamental events that underlie the development of
human cancer metastasis [7, 8].
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Circulating Tumor Cells (CTCs)
Circulating tumor cells (CTCs) represent cancer cells
that detach from a solid tumor mass and, using the
blood circulatory system, are in the process of colonizing
distant organs to give rise to metastasis [1]. CTCs have
been detected in the majority of cancers of epithelial ori-
gin, including breast, colon, prostate, and pancreas but
also in cancers of non-epithelial origin, such as glioblast-
oma multiforme and melanoma [7–12]. Most import-
antly, their presence has been correlated with a poor
prognosis in several major epithelial cancer types, sug-
gesting that CTCs contribute actively to the metastatic
process [7, 13, 14]. However, in patients, CTCs are
extraordinarily rare compared to normal blood cells (ap-
proximately one CTC among a billion normal blood
cells), and their isolation and molecular characterization
has been hampered for a long time by technological
constraints. Furthermore, variable expression levels of
cancer-associated cellular markers represent a major
challenge in identifying these rare cells in a viable state,
among a large number of blood cells, highlighting the
need for specialized technologies for their isolation and
characterization.
In the recent years, several platforms have been estab-
lished that take into account both cell surface expression
patterns as well as physical or functional properties of
CTCs for their isolation [9, 15–18]. For epithelial cancer
types, antigen-dependent isolation devices rely mostly
on the expression of cell surface Epithelial Cell Adhesion
Molecule (EpCAM) to isolate CTCs, given its high ex-
pression in most of the tumor cells of epithelial origin
[19]. For example, the only FDA-approved platform for
CTC enumeration is the CellSearch system, which uses
a two-step procedure to isolate CTCs [17, 18]. In the
first step, plasma components are removed by centrifu-
gation, while EpCAM-positive CTCs are captured using
immunomagnetic beads. In the second step, CTCs are
permeabilized and stained for the expression of add-
itional markers, such as the epithelial cytokeratins (CK)
8, 18, and 19. Meanwhile, contaminating leucocytes are
identified with a staining against CD45, a widely
expressed leukocyte marker. At the end of the proced-
ure, captured cells are placed on an integrated analyzer
for scanning and CTCs are identified as being positive
for the expression of CKs and DAPI, while being nega-
tive for CD45. Even though CellSearch is currently con-
sidered as the gold standard in capturing CTCs in a
clinical setting, a disadvantage of this technology is that
ultimately isolated CTCs are non-viable due to fixation
and additionally, the antigen-dependent approach for
CTC-isolation may in fact favor the enrichment of
CTCs with higher EpCAM expression, over CTCs
with lower EpCAM levels as a consequence of cancer
heterogeneity [20], dynamic protein turnover [21], or
the down-regulation of epithelial markers in favor of
mesenchymal-like traits, in a process known as
Epithelial-to-Mesenchymal Transition (EMT) [8, 22–
24]. As a consequence, new emerging technologies tend
to focus on antigen-independent methods for CTC iso-
lation, yet they are designed based on different princi-
ples. For example, isolation of CTCs independently of
the expression of tumor-associated antigens has been
achieved via size-based depletion of normal blood cells,
leveraging on the notion that CTCs are slightly bigger
than red or white blood cells (approximately 12-25 μm
for a single CTC, vs 8 μm and 7-15 μm, for red and
white blood cells respectively) [25, 26]. Filter-based
platforms such as Parsortix and ScreenCell capture lar-
ger CTCs, while smaller white blood cells (WBCs) and
blood components like platelets and red blood cells
(RBCs) flow through the microfluidic channels [27, 28].
Alternatively, the spiral biochip is another newly devel-
oped ultra fast, size-based microfluidic device that can
isolate larger CTCs from patient blood samples within
a few minutes. This chip relies on a combination of
hydrodynamic forces that are generated when blood
flows through spiral microchannels. These forces position
larger CTCs towards the inner walls of the spiral channel,
while smaller blood components are pushed towards the
opposite outer wall [29]. However, further studies need to
be performed with this technology to assess whether the
higher shear forces, compared to those that are normally
present in physiological blood circulation, could influence
some of the properties of CTCs. On the other hand, the
CTC-iChip combines an initial hydrodynamic cell separ-
ation of nucleated cells, including CTCs and WBCs, from
other blood components, followed by an immunomag-
netic depletion of antibody-tagged WBCs [7]. This
approach, similarly to the other size-based approaches
mentioned above, results in the antigen-independent
enrichment of CTCs from whole blood samples, allowing
their molecular characterization.
Antigen-independent isolation of CTCs from cancer
patients is key to understanding the biology of cancer
metastasis in a variety of cancer types, including those of
epithelial but also non-epithelial origin. Recently, using
the CTC-iChip and the Herringbone HBCTC-chip
microfluidic platforms, as well as density gradient centri-
fugation, CTCs were isolated from the blood of breast,
prostate and pancreatic cancer patients [7, 30, 31], as
well as patients with small cell lung cancer, glioblastoma
multiforme and melanoma [32–34]. Downstream, single
cell resolution transcriptional profiling of these cancer
cells that are en route to metastasis has revealed a great
degree of heterogeneity among them within the same
patient, but also among CTCs from different patients.
Interestingly, these studies revealed a role for non-
canonical WNT signaling in drug resistance and
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establishment of metastases in pancreatic and prostate
cancer patients [30, 31]. In human breast CTCs, a dy-
namic expression of epithelial versus mesenchymal
markers in response to treatment was observed using
quantitative RNA-in situ hybridization, demonstrating
for the first time a mesenchymal-like phenotype in hu-
man metastatic cells [8]. Similarly, in glioblastoma multi-
forme, mesenchymal markers were enriched in CTCs
over neural differentiation markers [33]. In small cell
lung cancer, CTCs were shown to be tumorigenic upon
transplantation in immunocompromised mice and more
importantly, the xenograft tumors matched those mor-
phological and genetic features of the primary tumor in
the patient of origin, and were predictive of treatment
response [32].
All together, recent technological breakthroughs are
allowing us to gain fundamental insights into CTC het-
erogeneity in different types of cancers and patients.
However, it is very important to highlight that in any
given tumor type, the number of CTCs present in the
bloodstream appears to largely exceed the number of
clinically detectable metastatic foci, indicating that most
CTCs will not lead to metastasis, and that only very few
will have those features that will enable them to seed a
metastatic disease.
CTC clusters
The identification and characterization of the subset of
metastasis-initiating cells among the CTC population in
patients is of paramount clinical importance. The major-
ity of CTCs circulate in the blood of cancer patients as
single cells, however they can also be found as clusters
of 2-50 cells, with the ratio of single vs clustered CTCs
varying significantly among different patients, and along
disease progression [7, 30, 31]. While the role of CTC
clusters in the metastatic process remained unknown for
a long period, recently, their presence in the blood circu-
lation of patients with metastatic breast, lung or prostate
cancer was correlated with poor metastasis-free survival
and overall survival, suggesting that CTC clusters are
key players in the spread of cancer cells to distant meta-
static sites [7, 35, 36]. By using the CTC-iChip technol-
ogy in combination with a micromanipulator, both
single CTCs and CTC clusters from patients with meta-
static breast cancer were recently isolated and subjected
to RNA sequencing profiling [7]. Data analysis revealed
that CTC clusters upregulate a set of genes that include
the cell-cell junction component plakoglobin. In breast
cancer patients, increased expression of plakoglobin in
the primary tumor is indicative of a decreased
metastasis-free survival, while in mouse xenograft
models, knockdown of plakoglobin expression in ortho-
topic mammary tumors suppresses spontaneous CTC
cluster formation and lung metastases [7].
In the same study, using two independent mammary
tumor mouse models, it was shown that CTC clusters
are oligoclonal in origin and do not arise from the aggre-
gation or proliferation of single CTCs within the circula-
tory system [7, 8]. Rather, CTC clusters arise when a
group of malignant cells detaches from a solid tumor
deposit and enters into the blood circulation. By color-
coding primary tumor cells to distinguish single versus
clustered CTCs, it was also shown that even though
single CTCs are more frequent in blood circulation, lung
metastases arise preferentially from CTC clusters. In
fact, CTC clusters were found to be up to 50 times more
likely to form lung metastatic deposits compared to sin-
gle CTCs in this experimental setup. Using in vivo flow
cytometry in mouse models to assess circulation half-life
of single and clustered CTCs, it was found that larger
CTC clusters are rapidly cleared (usually within 10 min)
from the blood circulation, due to their entrapment in
smaller capillaries at distant organs [7]. Thus, compared
to the 30 min half-life of single CTCs in blood circula-
tion, it is possible that current blood sampling tech-
niques underestimate the number of CTC clusters
released in circulation due to their shorter half-life.
However, the rapid clearance of CTC clusters at distant
organs indicates that clusters reach potential metastatic
sites at a higher rate compared to single CTCs. Whether
the higher metastatic propensity of CTC clusters corre-
lates with the faster rate at which they reach distant
organs in patients, or whether this indicates that
metastasis-initiating cells with stem-like properties are
preferentially enriched in clusters versus single CTCs is
currently unknown.
Stem-like properties of cancer cells
By definition, stem cells are cells that are resident in vir-
tually all normal tissues and have the ability, upon cellu-
lar division, to both self-renew and give rise to cells that
will differentiate into more specialized cell types [37, 38].
As a consequence to this definition, in cancer, the so
called “cancer stem cells” are defined as those cells with
stem-like properties, which can self-renew and differen-
tiate, resulting into a population of cells that has the
long-term ability to clonally reproduce the tumor itself
and its inherent heterogeneity [39, 40]. Functional
repopulation assays are currently the gold standard for
measuring stem-like properties of cells. For cancer biol-
ogy, serial transplantations in mice or in situ tracking
are used to ensure that cancer cells with stem-like prop-
erties have the long-term ability to clonally maintain the
tumor and regenerate the heterogeneous tumor mass.
These assays are designed in order to simultaneously as-
sess the self-renewal and differentiation potential of pu-
tative stem-like cancer cells. The principle for the serial
transplantation assay is that cancer stem-like cells must
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have the ability to re-establish the primary tumor, while
maintaining both heterogeneity and self-renewing ability
upon sequential transplantations into animal models
[41]. During in situ clonal assays, a population of cells is
initially labeled, most commonly by the addition of a
fluorescent marker, to allow long-term tracing of the
progeny in the recipient mouse, in order to assay again
for self-renewal and differentiation potential [42].
However, one of the major challenges in these studies
is to identify those expression markers that faithfully de-
fine a cancer stem cell phenotype. Undeniably, there is a
great degree of heterogeneity between stem-like cancer
cells themselves and among different tumor types [37,
38], arguing that the identification of faithful stem-like
markers in cancer cells is an extraordinarily difficult
task. The identification of a small population of cells
enriched with a tumor-initiating potential was first re-
ported in Acute Myeloid Leukemia (AML) and it was
based on the expression pattern of cell adhesion markers
CD34 and CD38 [43]. Using flow-sorting techniques it
was shown that a fraction of CD34+/CD38- but not
CD34+/CD38+ cells were able to initiate AML upon ser-
ial transplantations in immunodeficient mice. These
studies provided proof that not all tumor cells are equal
in their tumor-initiating potential and paved the way for
the identification, based on expression of cell surface
markers, of similar populations with stem-like properties
in other solid tumors. For instance, in brain and lung
cancer, the expression of CD133, a transmembrane pro-
tein with poorly understood signaling function, corre-
lates with tumor initiating potential upon serial
transplantations in immunodeficient mice [44, 45]. Simi-
larly, in colon cancer as well as in ovarian tumors,
cancer-initiating cells are highly enriched in the CD133
expressing fraction [46–48]. In pancreatic cancer, com-
bination of two distinct expression patterns, such as of
CD44/CD24 together with the epithelial-specific antigen
(ESA) or CD133/CXCR4, can identify the cancer stem-
like population [49, 50]. However, CD133 expression
combined with that of CXCR4, a mediator of cell migra-
tion, was also shown to enrich for a population that in
addition to stem-like features, also displayed a metastatic
potential in pancreatic cancer [50]. In breast and pros-
tate cancer in particular, the subpopulation of cancer
cells with stem-like properties is identified as being
enriched in the CD44+/CD24- fraction [51, 52]. In
breast cancer, combination of CD44 expression with
that of alcohol dehydrogenase (ALDH), which is also
expressed in hematopoietic progenitor cells, could fur-
ther refine the tumorigenic population [53, 54]. ALDH
alone was also used as an expression marker in both
breast and prostate cancer to identify a distinct popula-
tion of stem-like cells in addition to the CD44+/CD24-
fraction [55, 56].
Taken together, these studies indicate that combina-
tions of different cell surface expression markers have
been used to identify distinct tumor-initiating popula-
tions in solid tumors, but that use of these expression
markers may not yet be sufficiently refined to identify
unequivocal stem-like populations in different human
cancers, especially considering the high degree of muta-
tional and cellular heterogeneity of human tumors in the
metastatic setting, and upon resistance to therapeutic
agents [57]. Further, it has been shown that the percent-
age of putative stem-like cancer cells in each model may
vary dramatically, depending on experimental condi-
tions. Factors such as the use of different recipient
mouse strains, as well as assaying tumors at different
stage of progression and treatment may explain some of
the discrepancies between those studies aimed at asses-
sing the stem-like population in solid tumors (Reviewed
in [57]). Univocally though, the studies summarized
above point to the fact that, in order to dissect the het-
erogeneity within the putative stem-like cancer popula-
tions, those functional assays that are currently used to
assess stemness such as the serial transplantation assay,
will need to be redesigned in order to assay for both
self-renewal and differentiation potential in clonal popu-
lations arising from single cells. Tracing both self-
renewal, differentiation and tumorigenic potential to a
single cell level will also be crucial for identifying true
tumor-initiating cells endowed with stem-like potential
in cancer, and discriminating them from subpopulations
of cells that are only enriched in proliferation or survival
properties but lack true stem-like potential. To this re-
gard, there is also a need to reassess culture methods in
vitro, and most importantly ensure that clonal populations
can arise from single cells in vitro without the need to ex-
ogenously supplement saturating amounts of growth fac-
tors. Altogether, these studies point towards the need to
refine both the use of expression markers and related
functional assays, especially considering the possibility that
is now available, to interrogate cancer cells at higher reso-
lution and at the single cell level [58, 59].
Stem-like properties of cancer cells in circulation
Expression of cancer stem-like markers in various cancer
types has been shown to correlate with the occurrence
of metastasis and reduced survival in patients, support-
ing the hypothesis that cancer cells enriched in stem-like
features are the precursors of metastasis (reviewed in
[57, 60]). Recent single cell-resolution RNA sequencing
data obtained from CTCs of patients with prostate and
breast cancer may help gain insights into the expression
of stem-like markers, specifically in cancer cells as they
transit through the bloodstream, as CTCs isolated from
these cancer patients were shown to express CD44.
Moreover, 60 % of the CTCs profiled from prostate
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cancer patients were also enriched for ALDH7A1 and
other putative stem-like markers such as KLF4 [7, 31].
However, the expression dynamics and the heterogeneity
regarding the expression of these markers have not yet
been quantitatively assessed in CTCs. Most importantly,
it will be necessary to link the expression patterns of
these putative stem-cell markers in CTCs with enhanced
tumor-initiating and metastatic potential. To date, even
though CTCs isolated from patients are able to form tu-
mors in mice, they have not been assessed for their ability
to long-term self-renew and regenerate a highly heteroge-
neous cancer upon serial transplantations [7, 30]. Argu-
ably, additional functional assays should be implemented,
that can assess the stem-like properties of cancer cells at
the single cell level, and will enable the correlation of
stem-like marker expression with the metastatic potential
of putative stem-like CTCs.
On the other hand, it is increasingly evident that
stem-like properties may represent an extraordinary ad-
vantage for CTCs as they encounter a number of chal-
lenges during the metastatic process. For example, a first
major challenge that CTCs face, is the need to suppress
anoikis, a form of programmed cell death that is trig-
gered in epithelial cells upon loss of adhesion to sur-
rounding cells. Once in blood circulation, CTCs are
striving to survive in a hostile, immune cells-rich envir-
onment while they are subjected to high shear forces
that challenge their structural integrity. Additionally, if
successful, CTCs that reach distant organs will need to
adapt to the foreign environment in order to seed a
metastatic lesion. In this context, it is not surprising that
the majority of molecular pathways that regulate self-
renewal, such as PI3K/AKT, PTEN, JAK/STAT, seem to
be also essential for cancer onset and metastasis, while
increasing survival signals that provide resistance to cell
death and chemotherapeutic agents [61–64]. Whether
stem-like properties are a feature of some CTCs and
whether they are enriched in single versus clustered
CTCs remains an open question. The fact that CTC
clusters are more prone to establishing metastases com-
pared to single CTCs in mouse xenograft models could
indicate that stem-like properties are enriched in CTC
clusters over single CTCs. On the other hand, it is also
possible that stem-like properties are equally enriched in
both single CTCs and CTC clusters, but the higher
metastatic propensity observed with CTC clusters is re-
flective of their physical advantages, such as the greater
likelihood to be trapped in small capillaries at distant
sites. To this regard, the presence of cell-cell junctions
in CTC clusters could help overcome anoikis in the
bloodstream and provide survival signals along the
metastatic process, including during the early dissemin-
ation to distant organs. The actual contribution of spe-
cific mutations and deregulated signaling pathways,
mesenchymal-like features and CTC-clustering for the
generation of metastasis-initiating cells remains to be
addressed (Fig. 1).
Another important hint connecting stem-like proper-
ties with CTCs is the protocol that has been imple-
mented for CTC cultures [65]. After testing a number of
different culture conditions it was shown that CTCs
could be propagated in vitro only if they were cultured
in hypoxic conditions, as tumor spheres in serum-free
media supplemented with epidermal growth factor
(EGF), B27 and basic fibroblast growth factor (FGF2).
Interestingly, given the fact that CTCs have a limited
half-life in blood circulation, the requirement for hyp-
oxic conditions for their propagation could reflect the
oxygen levels within the tumor tissue of origin, rather
than the oxygen concentration within the arterial or
venous circulation. Similarly to CTCs, culture of human
embryonic stem cells (hESCs) under hypoxic conditions
is also important for regulating pluripotency and prolif-
eration of these cells in vitro [66]. Additionally, for hESC
and human induced pluripotent cell (hIPSC) culture in
vitro, FGF2 is required for promoting self-renewal and
survival in several different ways, such as via the activa-
tion of the PI3K/AKT and MAPK signaling pathways
[67], but also through promotion of cell adhesion,
highlighting the importance of cell-cell contact in main-
tenance of self-renewal and survival in hESCs [68]. To
this regard, hESCs can be propagated in an undifferenti-
ated state in vitro essentially indefinitely by forming ra-
ther tightly packed colonies of individual cells that are
connected through various complexes, such as adher-
ence junctions, tight junctions, desmosomes and gap
junctions [69]. Undoubtedly, not all stem cells require
FGF2 signaling for maintaining pluripotency in vitro. In
fact, mouse ESCs that are functionally very similar to
hESCs, are destabilized by FGF2 and depend on the acti-
vation of the LIF/Stat3 signaling pathway [70]. However,
as opposed to conventional hESCs that display very poor
clonal efficiency and survival when dissociated to single
cells, mESCs not only tolerate single cell dissociation
but also manage to maintain pluripotency under these
conditions [71]. Therefore, we speculate that in systems
such as hESCs that depend on FGF2, the link between
pluripotency and cell-cell adhesion could support a
model in which CTC clusters are enriched in stem-like
properties. Further, not only cell-cell adhesion but add-
itionally other signaling molecules could be promoting
stemness in CTCs [30, 31, 72].
Recent molecular studies on CTC clusters indicate
that there is a great degree of cellular and molecular het-
erogeneity among different CTC clusters, even among
those profiled from the same patient [7, 30, 31]. This
heterogeneity unquestionably also reflects differences in
expression profiles of individual CTCs that form the
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same cluster and potentially also reflects the expression
of stem-like features. Therefore, it is possible that only a
few cells within a CTC cluster are in fact retaining stem-
like properties and are able to form metastases, while
other surrounding cells display reduced or no stem-like
characteristics and do not contribute to the metastatic
process. Additionally, other, non-cancerous cell types,
such as macrophages, platelets and even fibroblasts
and epithelial cells, were shown to bind CTC clusters
[7, 73–75]. These interactions can affect the molecular
profile of the cells they are in direct contact with, further
promoting heterogeneity and enhancing the overall fitness
of CTCs. For example, platelets that bind to CTCs may re-
lease transforming growth factor β (TGF-β), which in turn
can provide additional survival signals [75]. Moreover,
platelets have also been shown to induce EMT, a tran-
scriptional program which is orchestrated by a number of
embryonic transcription factors, that was also suggested
to promote the expression of stem-like markers, confer-
ring malignant traits such as invasiveness and resistance
to apoptosis [22, 76]. Alternatively, CTC-associated
platelets can release adenine nucleotides and facilitate
extravasation by inducing an opening at the endothelial
barrier [77], while macrophages that bind to CTCs can
promote tissue remodelling and help extravasation
through capillary walls in the lung [78]. Moreover,
tumor-derived fibroblasts or endothelial cells that bind
to CTC clusters could act as passenger stromal cells
that form part of the tumor microenvironment at the
distant site, therefore facilitating the initial growth of
CTCs and ultimately promoting metastasis [74, 75].
Therefore, it is evident that in order to dissect the
heterogeneity that is present in CTCs, additional
studies that aim at profiling these cells at single cell
resolution are necessary. In respect to identifying
stem-like features in CTCs, it will be important to
first identify robust expression markers that faithfully
report the stem-like potential of these cells, as well as
appropriate functional assays that assess their self-
renewal and differentiation potential while also evalu-
ating their metastatic propensity.
Conclusions and open questions
One of the most important challenges for cancer stem
cell biology today represents the identification of those
markers that robustly define cancer stem cells within a
highly heterogeneous human tumor, and along the meta-
static cascade. With regard to metastasis, it will be inter-
esting to identify whether markers that confer stem-like
properties are specifically enriched in a subset of CTCs.
Even more importantly, mechanistic studies will need to
address the direct molecular mechanisms by which these
markers contribute to the metastatic cascade. Undoubt-
edly, there is also an increasing need to refine those
Fig. 1 Stem-like features of CTCs. Schematic representation of different hypotheses describing how single CTCs or CTC-clusters could acquire
stem-like features
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functional assays currently employed for assessing stem-
like as well as tumorigenic potential in cancer, so that
cancer cells are interrogated at single cell resolution.
This is a crucial step to enable the identification of bona
fide stem-like cancer cells among a highly heterogeneous
cell population. Since cancer is manifested on a genetic-
ally diverse population of cells, it will also be important
to identify the mutational events that are associated with
enhanced stem-like properties of cancer cells. To this re-
gard, it was recently shown that mutations in the PI3K
pathway have the ability to induce multipotency in
breast cancer [79, 80]. Whether other mutations, and
more importantly whether low frequency mutations that
can be easily overlooked at the time of diagnosis, have
the ability to fine-tune malignant properties of cancer
cells by building upon an already tumorigenic program,
enhancing stem-like features and becoming predominant
during disease progression, remains an open question
(Fig. 1).
Moreover, the contribution of non-genetic elements
still needs to be addressed, and in particular the poten-
tial role of DNA methylation, chromatin structure and
other epigenetic modifications in the metastatic process.
Can certain genetic or epigenetic signatures promote
stem-like features and are these signatures enriched in a
subset of CTCs? Further, how do stromal cells relate to
multipotency and do they act by promoting and/or
maintaining stem-like features in CTC clusters?
Another interesting aspect of CTC biology is the po-
tential link with anti-cancer immunotheraphy strategies.
For example, CTCs isolated from breast cancer patients
with advanced metastatic disease have been shown to
express Programmed Death Ligand 1 (PD-L1) in order
to avoid immune system detection by inhibiting T cell-
mediated immune response [81]. The PD1/PD-L1 inter-
action has been the basis for the development of a num-
ber of immunotherapies in patients with several solid
tumors. In such cases, treatment with anti-PD-L1 block-
ing antibody has shown very promising clinical
responses in a subset of patients [82]. Similarly, in mel-
anoma, PD-1 as well as Cytotoxic T lymphocyte
antigen-4 (CTLA-4), another key negative regulator of T
cell activation, have been exploited towards the develop-
ment of immune checkpoint inhibitors [83–87], al-
though at present it is very hard to predict which
patients will benefit from this therapeutic strategy. In
this context, CTC analysis may help to stratify patients
and to identify those who would benefit from an im-
munotherapy approach.
Clinically, a fundamental question is whether we can
learn how to target the metastasis-initiating cell popula-
tion within heterogeneous tumors. To date, targeted
cancer therapies have not been successful in preventing
the development of metastases in cancer patients,
highlighting an enormous need for metastasis-tailored
drug discovery programs. Along this line, the isolation
and detailed molecular profiling of CTCs represents an
outstanding opportunity to define the molecular, as well
as the stem-like features of metastasis-initiating cells,
contributing to advancing our knowledge on the biology
of metastasis in patients with cancer.
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1) There are no serious deficiencies in the manuscript.
Two minor observations follow: With reference to
the spiral biochip for CTCs separation (pg.4, from
line 23 on): could the authors comment on the
potential effects (membrane damages, pathways
activation, etc) elicited by shear forces on the
exposed cells?
Authors’ response: In regard to the spiral biochip,
we have now addressed this point in the text. We
indicate that further studies will be needed to
determine a potential effect of the higher shear forces,
used by the spiral biochip, on the properties of CTCs.
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2) The authors state that “..cell-cell adhesion in CTCs
is essential for promoting stem-like features..” (pg.8,
from line 41 on): could this be linked to the fact that
CTCs clusters appear to be enriched in stem-like
cells?
Authors’ response: We agree with the speculation
raised by the Reviewer. This point is now addressed
in greater detail in the text.
Minor issues: Page8, line 58: “we shown” should
maybe be “were shown”?
Authors’ response: We thank the Reviewer for noticing
the typo. This has now been corrected in the text.
Reviewers’ report 2: Luca Pellegrini, Université Laval,
Canada
Original comments
Summary: The review addresses how single and clus-
tered tumor cells that circulate in the bloodstream of
cancer patients (CTCs) contribute to metastasis forma-
tion. It provides an overview of the methods used to
isolate CTCs and how they have been used to under-
stand the origin, fate, molecular fingerprint, and malig-
nancy of this type of cell. An extensive part of the
review is dedicated in putting together a case for con-
sidering CTCs as stem-like cells, a possibility with im-
portant implications for the search of antimetastatic
pharmacological approaches. I found it a very well writ-
ten and highly informative work from a junior faculty
that has already contributed outstanding work in the
CTC field: readers of Biology Direct that are in differ-
ent fields of cell biology should find the review useful
and educative; and CTC experts should appreciate its
vision and sharpness in identifying the challenges ahead
and the outstanding questions that remain to be
addressed.
Authors’ response: We thank the Reviewer for his very
positive comments on our review.
Recommendations:
1) I would recommend to expand the chapter
“conclusions and open questions”: some clever and
important ones are scattered throughout the text;
so, it would be best to repeat them here.
Authors’ response: We thank the Reviewer for his
suggestion. We have expanded this section in our
revised manuscript to better describe the need to
identify reliable stemness-associated markers in
cancer, especially at a single cell resolution. We also
highlight the need to refine the functional assays
currently employed for assessing stem-like and
tumorigenic potential in cancer cells.
2) I would also recommend to address the link between
CTC and anti-cancer immunotherapy.
Authors’ response: We have also addressed this point
in the section “conclusions and open questions”,
giving special emphasis to the PD-L1/PD1 interaction
and the fact that, while very promising, it is at
present hard to predict which patients will benefit
from an immunotherapy approach. In the future, the
analysis of CTCs may serve a tool to stratify patients
in this regard, and to identify those that are more
likely to benefit from such therapy.
Minor issues:
1) Define and explain EpCAM
Authors’ response: We have adapted the text and
now provide a better definition and explanation of
the choice of EpCAM as a marker for epithelial CTC
isolation.
2) Explain the Cell Search system for the readers that
are not familiar with it.
Authors’ response: Following the reviewer’s
suggestion, we have now expanded the part referring
to the CellSearch system and explained it in greater
detail.
3) Page 4, line 18: clarify if this is the size of single or
clustered CTC?
Authors’ response: We have clarified this point and
thank the Reviewer for noticing this omission.
4) Page 5, line 17-18: specify the relative percentage
(or ratio) of single vs. clustered CTC.
Authors’ response: We now provide a statement on
the ratio of single vs clustered CTCs, yet specifying
that it can vary dramatically among different
patients and along disease progression.
5) Page 8, line 44-46: this sentence is not clear.
Authors’ response: We have now reworded and
clarified the sentence.
6) Page 8, line 49: explain the type of heterogeneity.
Authors’ response: We now state that CTC clusters
have a high degree of both cellular and molecular
heterogeneity.
7) Page 8, line 58: correct “we shown”.
Authors’ response: We have corrected this in the
text, and thank the Reviewer for noticing the typo.
8) Do not abbreviate/use acronyms for things that are
mentioned only twice (e.g. EMT).
Authors’ response: We have followed this suggestion
and corrected it throughout the text.
Reviewers’ report 3: Sirio Dupont, University of Padova,
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1) On my point 7, Page 9, around line 40. The authors
added in this revised version the requirement for
Wnt in the maintanance of hESC pluripotency, and
make a parallel with CTC culture conditions.
However, the role of Wnt in hESC is highly
controversial in the field, as many found evidence
that Wnt actually promotes hESC differentiation,
recapitulating the role of Wnt signalling in the
epiblast of mammalian embyos (see for example
Davidson et al., PNAS 2012 and Blauwkamp Nat
Commun 2014). I would strongly recommend to
delete the last phrase of the paragraph as the
Wnt-based parallel between CTCs and hESC
appears extremely weak and fails to acknowledge the
vast literature of the hESC field on this topic.
Authors’ response: We agree with the Reviewer in
that the role of Wnt in hESC is controversial.
Accordingly, we have removed the last sentence of the
paragraph.
2) On my point 8. I fear there was a partial
misunderstanding. The authors draw a parallel
between the culture conditions used for CTCs with
those used for hESC, and use this to strenghten the
notion that CTCs display some stem cell properties.
My warning was on the fact that hESC themselves
are not all the same, and do require different culture
conditions. The issue is not on mouse vs. human
stem cells, but on the fact that two types of
mammalian pluripotent cells exist: naive pluripotent
cells, like the usual mESC but also like the ground-
state hPSC recently derived (which, for example,
both require constitutive Wnt activation for self-
renewal), and primed pluripotent cells, like mouse
Epiblast-SC or the usual hESC (which instead re-
quire FGF and TGFbeta stimulation, and differenti-
ate upon Wnt activation). These populations are
very similar (much more similar than hESC and
CTCs), yet they display opposite or anyway different
culture conditions (see Weinberger NRMCB 2016).
Therefore, it appears arbitrary to establish a parallel
with only one human pluripotent stem cell popula-
tion only because this one fits. However, I respect
the author’s choice to keep their idea.
Authors’ response: We thank the Reviewer for his
comment. However, we clearly point out in the
manuscript that the parallel between culture
conditions for CTCs and hESCs is speculative, yet not
conclusive about their identity.
Original comments
Summary: The review starts from the very interesting
finding that circulating tumor cells (CTC) can be found
not only as single cells but also in small clusters, both in
mouse models for metastatic cancer and in human
patients suffering from solid tumors. Moreover, the au-
thors found that CTC clusters display higher tumor-
seeding ability in mice, and that their presence in the
blood of human patients is highly predictive of disease
relapse and metastatic disease. The authors discuss their
findings in light of the notion that metastasis is the ac-
tual cause of death form many cancer patients, thus call-
ing for a better understanding of how cells form
metastasis, and also discuss the possible links between
CTC biology and other traits that have been previously
associated with metastatic propensity, such as EMT and
stem-like properties. The topic is very up-to-date and in-
teresting, as it opens a series of challenging and partially
unanswered questions.
Authors’ response: We thank the Reviewer for his fa-
vorable comments on our manuscript.
Recommendations:
1) In several points of the review the authors discuss
their findings in light of current mainstream theories
about metastasis. For the sake of the non-expert
audience, I think it would be valuable to sometimes
briefly introduce these theories in a more balanced
way, by providing the reader also with the possible
pitfalls of a given idea/theory, mostly if these pitfalls
are based on experimental evidence. In my idea, a
review should not only serve to put a paper in the
mainstream, but also to highlight what we still don’t
know or don’t fully understand in a field, and which
should be a priority for future studies.
Authors’ response: We fully agree with the point of
view of the Reviewer. In our review, we attempted to
provide a wide overview of the opportunities as well
as the limitations of the CTC field, with a focus on
those assays used for their isolation and
characterization, and a special attention to describe
what is currently known in regard to their stem-like
properties. We also provide a number of speculations
and hypotheses that may be of interest to a broad
readership.
2) Page 1, around line 45. In the discussion of the
correlation between CTC and metastasis in human
patients, it would be interesting to know whether
prospective studies have been carried out to causally
link the presence/abundance of CTCc and the
prognosis, above correlative studies. If not yet
available, this review could be the right place to
recommend such important type of studies.
Authors’ response: A high number of prospective
studies have been conducted for CTCs in several
cancer types, including breast, colorectal and lung
cancer (e.g. see Li et al., Oncotarget, 2016; Bork et al.,
Br J Cancer, 2015; Lucci et al., Lancet Oncology,
2012; Mego et al., Breast Cancer Research, 2015;
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Wallwiener et al., BMC Cancer, 2014; Rack et al.,
JNCI, 2014). These studies clearly pointed to a high
prospective value of CTCs in predicting disease
progression or response to therapy. In this review, we
therefore decided to not point out the need for
additional prospective studies.
3) Page 5: was the correlation between cluster CTC
and malignancy observed in human cancer patients
corrected for the grade/burden of the primary
tumor? In other words, are cluster CTC observed
only in patients with bigger/more advanced tumors?
If so, maybe the presence of CTC is only a readout
of the tumor malignancy, rather than a cause of
recurrence per sé?
Authors’ response: These studies focused on patients
with a progressing metastatic disease, all generally
characterized by a high tumor burden. No direct
correlation between the presence of CTC clusters and
tumor grade or burden was found. We have now
updated the text, where we clarify that a correlation
between CTC clusters and poor prognosis was evident
in patients with a metastatic disease.
4) Page 5: What can we learn, or at least estimate, on
human disease from the CTC half-life in mice and
the observed CTC frequencies in human patients?
Experiments in mice were based on the i.v. injection
of many cells (2*10^5), which is perhaps very high
compared to the real situation in humans. Still, the
authors easily tracked single-cell and cluster CTCs
in human samples. It would be interesting to esti-
mate the number of CTC released in the blood by
human tumors, as a tentative measure of the fre-
quency and importance of the phenomenon.
Authors’ response: We agree with the Reviewer that
it would be extremely interesting to estimate the
number of CTCs that are directly released in
circulation from a human tumor lesion. Especially, it
would be interesting to assess how many of them,
and how quickly, are entrapped within small
capillaries during their first pass through the
circulatory system. Given the short half-life of CTCs
in mouse models, we believe that such studies would
be exceptionally challenging in patient samples. In
our review, we dedicate a full paragraph discussing
the implications of a short circulation half-life of
CTCs. Clearly, more studies will be needed to better
estimate and describe this process in cancer patients.
5) Page 6: It should be noted and discussed here that
the concept of CSC, although an interesting one, is
not universally accepted and is for sure greatly
biased by the experimental system: it is indeed
widely known that the estimated CSC (or tumor-
seeding) frequency in cancer cell populations can
widely differ from small percentages to basically
100 % of cells depending on the mouse strain and on
the conditions in which the assay is carried out. Un-
less these studies have been revised and updated re-
cently, this should be incorporated in the discussion
as a precautionary information, because this suggests
the possibility that the “tumor initiating cell” pheno-
type, on which the definition of a CSC marker is
often based, reflects cell populations with increased
proliferation or survival ability, rather than true
“stem cells”.
Authors’ response: With this comment, the Reviewer
raises a very important point. We have addressed
this comment in two parts. First, we comment that
using different recipient mouse strains but also
assaying tumors at different stages of progression
may yield significant differences in the putative
cancer stem cell population. Second, we note that the
functional assays currently used are not refined
enough to distinguish bona fide cancer stem cells
from cells with increased proliferation or survival
ability, since they interrogate these properties at a
population level as opposed to the single cell level.
6) Page 8 The finding that hypoxia needs to be used in
vitro to culture CTCs is not expected, but
something strange, because CTC are exposed to the
highest oxygen concentrations into the bloodstream.
This should be mentioned and discussed also
because hypoxia changes a wide number of
parameters above and beyond the activity of HIFs,
including gene expression and metabolism, which
might be not so relevant to mimic in vitro the vivo
situation.
Authors’ response: We have now expanded the
paragraph that discusses CTC culture in hypoxic
conditions, to comment on this specific point. For
what concerns oxygen levels in circulation, we would
like to point out that these are known to vary
dramatically and rapidly, from arterial to venous
blood. For example, venous blood is thought to have
a much lower oxygen concentration than the
intestinal tissue or the kidney. Given the short half-
life of CTCs in circulation, the need for hypoxic con-
ditions could rather reflect that these cancer cells
were adapted to a hypoxic environment within their
tumor tissue of origin. We provide now a better de-
scription of this phenomenon within the text, and we
thank the Reviewer for highlighting this aspect.
7) Indeed the argument itself that a culture condition
(e.g. hypoxia or FGF) suitable for hESC can teach us
something significant on other stem cells, including
cancer stem cells, is very simplistic, and tends to
draw the idea that stem cells are all the same. Just to
make an example, hESC and mESC, despite a very
high degree of similarity, have COMPLETELY
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different culture conditions, such that one type does
not survive in the conditions suitable for the other
(and in particular in the presence of FGF). This last
part should be carefully reconsidered.
Authors’ response: In this particular case we
respectfully disagree with the comment of the
Reviewer. When considering human cells, these
culture conditions seem to strongly favor the
propagation of stem-like cells in multiple systems,
therefore we still believe that it is important to specu-
late on this observation in the context of this review.
With this in mind, we are certainly not arguing that
stem cells are all the same. In fact, we agree that
mouse ESCs require very different propagation condi-
tions, and we have now pointed out this aspect in the
text. The updated text should now provide more clar-
ity and a better background concerning propagation
conditions for stem-like cells.
Minor issues:
1) Page 4, around line 12 The problem of counter-
selection against CTCs displaying mesenchymal
traits should be better explained in light of the find-
ings that in some solid tumors the most aggressive
cells (in terms of metastatic potential and cancer-
stem cell traits) are thought to be the ones undergo-
ing EMT. This is of course still a matter of debate
(i.e. the fact that EMT is truly observed in tumors,
and instrumental for metastasis) and requires a bit
more of explanation.
Authors’ response: We thank the reviewer for his
comment. We have better described the concept of
EMT later in the paper, when discussing stem-like
properties of cancer cells in circulation.
2) Page 6, around line 55 Here the authors mix two
different concepts: one thing is the identification of
bona fide universal CSC markers in a given tumor
type; another is the cell of origin of tumors. That
tumors can form when mice are manipulated to
express an oncogene into a physiologic stem cell
compartment, such as LGR5+ intestinal stem cells,
is not so surprising, and not so informative on the
actual cell of origin of cancer (by definition, the
activated oncogene will be present in the stem cell
but also in all its progeny). The real and often
unanswered question is whether oncogenic
mutations in normal differentiated cells can
reprogram those cells to a stem-cell phenotype,
which at least in part recapitulates traits of the
physiological stem cells of the tissue of origin. Please
also remember that LGR5 was isolated as a normal
stem cell marker based on the hypothetical assump-
tion that cancer cells recapitulate traits of the
physiologic stem cell (VanDeWetering and Clevers
original paper), but how many of the physiological
stem cell markers identified thereafter do follow this
rule and are also found in cancer stem cell
populations?
Authors’ response: We have rephrased this part of
the text according to the Reviewer’s suggestion. For
colon and ovarian tumors we indicate that the use of
the bona fide cancer stem cell marker CD133
enriches for cancer-initiating cells. We have deleted
the reference to LGR5+, as the Reviewer is correct
and it may generate confusion in regard to the con-
cepts of cell of origin versus cancer stem cell.
3) Page 7, after line 30 The idea that metastatic cells
are endowed with stem-like properties is not entirely
new and should be referenced.
Authors’ response: We agree with the Reviewer and
have changed the text accordingly.
4) It seems to me however that there is a logical gap
between what the authors originally observed in
Aceto et al., Cell 2014, and the link between CTC
and CSC phenotypes. The authors originally used a
clonal cell line such as MDA-LM2, and there is to
my knowledge poor evidence that these cells can be
fractionated into stem-cells and non-stem-cells (i.e.
differentiated). To which extent a homogeneous sys-
tem like MDA-LM2 is informative on heterogeneous
cancer populations containing both stem and non-
stem cancer cells?
Authors’ response: We respectfully disagree with the
Reviewer in this case. MDA-MB-231 cells have been
originally derived from a pleural effusion of a Cauca-
sian breast cancer patient, and they are not consid-
ered a clonal cell population. MDA-MB-231 cells
have also been shown by several groups to contain a
stem-like subpopulation, usually referred to as the
CD44+/CD24- subpopulation, with enhanced invasive
and tumorigenic properties, as well as a population
of non stem-like cells.
5) Page 9, around line 28 The term “pluripotency” is
usually restricted to very early embryonic stem cell
populations. The papers referenced here show the
capacity of one committed mammary precursor
population to revert to a more primitive state and
differentiate into other mammary lineages into
which it would not differentiate in the physiologic
state. Please use the term “multipotency” as in the
title of these papers.
Authors’ response: We agree with the Reviewer and
have accordingly replaced the term pluripotency for
the term multipotency within the text.
6) Page 9, around line 30 It is not clear why a low
frequency mutation should be particularly
interesting: the tenet is that a mutation is retained
Gkountela and Aceto Biology Direct  (2016) 11:33 Page 11 of 14
proportionally to the selective advantage it provides
to cancer cells, and acquisition of stem-like features
should be an advantage for the primary tumor, not
only for CTCs or for metastasis.
Authors’ response: We agree with the comment of
the reviewer. However, it is important to mention
that the mutational profile in patients is dynamic
and it evolves as a function of time and resistance to
therapy. Low-frequency mutations that may confer
stem-like properties and are detected in a minority of
cells at a certain point should not be overlooked,
since they may become prevalent during disease pro-
gression. We have adapted the text to better describe
this concept.
7) Finally, something that is completely missing and
may merit some discussion is how CTC clusters are
formed in the first instance, as opposed to single-cell
CTC, and how do they extravasate. Much work has
been done in recent years on the ability of cancer
cells to undergo collective cell migration instead of
the more classical amoeboid single-cell migration.
However, this was used in some cases to advocate
against the need of EMT in solid tumors (EMT
would facilitate the detachment of single cells from
the epithelial mass and reprogram the cell to a mi-
gratory behavior). How then these different aspects
would merge in the case of CTC clusters?
Authors’ response: We agree with the Reviewer that
the processes of CTC intravasation and extravasation
are of great importance. While we feel that the
intravasation processes (e.g. via collective versus
single cell migration) are beyond the scope of this
review, we have now mentioned two studies that
highlight possible extravasation mechanisms of CTCs,
mostly in the context of their cellular heterogeneity,
i.e. their interaction with platelets.
Abbreviations
ALDH, alcohol dehydrogenase; AML, acute myeloid leukemia; CD, cluster of
differentiation; CK, cytokeratin; CTCs, circulating tumor cells; CTLA-4, cytotoxic
T lymphocyte antigen-4; CXCR4, C-X-C Chemokine Receptor Type-4; DAPI,
4’,6-diamidino-2-phenylindole; EGF, epidermal growth factor; EMT, epithelial-
to-mesenchymal transition; EpCAM, Epithelial Cell Adhesion Molecule; ESA,
epithelial-specific antigen; FBF2, basic fibroblast growth factor; hESCs, human
embryonic stem cells; hIPSCs, human induced pluripotent cells; JAK, janus
kinase; KLF4, kruppel-like factor 4; LGR5, leucine-rich repeat-containing
G-protein coupled receptor 5; MAPK, mitogen-activated protein kinase; PD1,
programmed death 1; PD-L1, programmed death ligand 1; PI3K, phos-
phatidylinositol 3-kinase; PTEN, phosphatase and tensin homolog; RBCs, red
blood cells; STAT, signal transducer and activator of transcription; TGF-β,
transforming growth factor-β; WBCs, white blood cells; WNT, wingless-type
MMTV integration site
Acknowledgements
We thank the European Research Council (ERC), the Swiss National Science
Foundation (SNSF), the Krebsliga Beider Basel, the L. & Th. La Roche
Foundation and the University of Basel for supporting our work. We are also
grateful to all members of N.A.’s lab for critical review of the manuscript.
Funding
N.A.’s lab is supported by the European Research Council (ERC), the Swiss
National Science Foundation (SNSF), the Krebsliga Beider Basel, the L. & Th.
La Roche Foundation and the University of Basel.
Availability of data and materials
Not applicable.
Authors’ contributions
S.G. and N.A. reviewed publicly available literature and wrote the manuscript.
Both authors read and approved the manuscript.
Authors’ information
N.A. is the Group Leader of the Cancer Metastasis Group and Assistant
Professor of Oncology at University of Basel, Switzerland. S.G. is a Senior
Postdoctoral Fellow in the Cancer Metastasis Group at University of Basel,
Switzerland.
Competing interests
N.A. is listed as an inventor in patent WO2015061091 on “Treating cancer, by
measuring level of CTC clusters in sample obtained from patient with breast
or epithelial cancer, administering treatment to prevent or reduce metastasis”
owned by the Massachusetts General Hospital, Boston, MA, USA. The authors
declare that they have no non-financial competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Received: 4 April 2016 Accepted: 19 July 2016
References
1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell.
2011;144:646–74.
2. Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer
metastasis: historical perspective. Cancer Res. 2010;70:5649–69.
3. Weinberg RA. The biology of cancer. New York, NY: Garland Science, Taylor
& Francis Group; 2007.
4. Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer.
2006;6:449–58.
5. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-
specific colonization. Nat Rev Cancer. 2009;9:274–84.
6. Weigelt B, Peterse JL, Veer LJ v ‘t. Breast cancer metastasis: markers and
models. Nat Rev Cancer. 2005;5:591–602.
7. Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA,
et al. Circulating tumor cell clusters are oligoclonal precursors of breast
cancer metastasis. Cell. 2014;158:1110–22.
8. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating
breast tumor cells exhibit dynamic changes in epithelial and Mesenchymal
composition. Science. 2013;339:580–4.
9. Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, et al.
Isolation of circulating tumor cells using a microvortex-generating
herringbone-chip. Proc Natl Acad Sci U S A. 2010;107:18392–7.
10. Krebs MG, Hou JM, Sloane R, Lancashire L, Priest L, Nonaka D, et al. Analysis
of circulating tumor cells in patients with non-small cell lung cancer using
epithelial marker-dependent and -independent approaches. J Thorac Oncol.
2012;7:306–15.
11. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE. Detection of
melanoma cells in peripheral blood by means of reverse transcriptase and
polymerase chain reaction. Lancet. 1991;338:1227–9.
12. Ting DT, Wittner BS, Ligorio M, Vincent Jordan N, Shah AM, Miyamoto DT,
et al. Single-cell RNA sequencing identifies extracellular matrix gene
expression by pancreatic circulating tumor cells. Cell Rep. 2014;8:1905–18.
13. Yu M, Stott S, Toner M, Maheswaran S, Haber DA. Circulating tumor cells:
approaches to isolation and characterization. J Cell Biol. 2011;192:373–82.
14. Alix-Panabieres C, Pantel K. Circulating tumor cells: liquid biopsy of cancer.
Clin Chem. 2013;59:110–8.
Gkountela and Aceto Biology Direct  (2016) 11:33 Page 12 of 14
15. Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schütze K, et al. Isolation by
size of epithelial tumor cells: a new method for the immunomorphological
and molecular characterization of circulating tumor cells. Am J Pathol.
2010;156:57–63.
16. Riahi R, Gogoi P, Sepehri S, Zhou Y, Handique K, Godsey J, et al. A novel
microchannel-based device to capture and analyze circulating tumor cells
(CTCs) of breast cancer. Int J Oncol. 2014;44:1870–8.
17. Beije N, Jager A, Sleijfer S. Circulating tumor cell enumeration by the cell
search system: the clinician’s guide to breast cancer treatment? Cancer
Treat Rev. 2015;41:144–50.
18. Miller MC, Doyle GV, Terstappen LW. Significance of circulating tumor cells
detected by the Cell Search system in patients with metastatic breast
colorectal and prostate cancer. J Oncol 2010;617421. doi: 10.1155/2010/617421
19. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, et al. EpCam
protein expression in human carcinomas. Hum Pathol. 2004;35:122–8.
20. Soysal SD, Muenst S, Barbie T, Fleming T, Gao F, Spizzo G, et al. EpCAM
expression varies significantly and is differentially associated with prognosis
in the luminal B HER2(+), basal-like, and HER2 intrinsic subtypes of breast
cancer. Br J Cancer. 2013;108:1480–7.
21. Lustberg MB, Balasubramanian P, Miller B, Garcia-Villa A, Deighan C, Wu Y,
et al. Heterogeneous atypical cell populations are present in blood of
metastatic breast cancer patients. Breast Cancer Res. 2014;16:R23.
22. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The
epithelial-mesenchymal transition generates cells with properties of stem
cells. Cell. 2008;133:704–15.
23. Morel AP, Lièvre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation
of breast cancer stem cells through epithelial-mesenchymal transition. PLoS
One. 2008;3(8):e2888. doi:10.1371/journal.pone.0002888.
24. Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, et al.
Anti-epithelial cell adhesion molecule antibodies and the detection of
circulating normal-like breast tumor cells. J Natl Cancer Inst. 2009;101:61–6.
25. Zheng S, Lin H, Liu JQ, Balic M, Datar R, Cote RJ, et al. Membrane microfilter
device for selective capture, electrolysis and genomic analysis of human
circulating tumor cells. J Chromatogr A. 2007;1162:154–61.
26. Bergman RA, Afifi AK, Heidger PM. Atlas of Microscopic Anatomy. Section 4:
Blood. Philadelphia: WB Saunders; 1996.
27. Xu L, Mao X, Imrali A, Syed F, Mutsvangwa K, Berney D, et al. Optimization
and evaluation of a novel size based circulating tumor cell isolation system.
PLoS One. 2015;10(9):e0138032.
28. Freidin MB, Tay A, Freydina DV, Chudasama D, Nicholson AG, Rice A, et al.
An assessment of diagnostic performance of a filter-based antibody-
independent peripheral blood circulating tumour cell capture paired with
cytomorphologic criteria for the diagnosis of cancer. Lung Cancer.
2014;85:182–5.
29. Warkiani ME, Khoo BL, Wu L, Tay AK, Bhagat AA, Han J, et al. Ultra-fast, label-
free isolation of circulating tumor cells from blood using spiral microfluidics.
Nat Protoc. 2016;11:134–48.
30. Yu M, Ting DT, Stott SL, Wittner BS, Ozsolak F, Paul S, et al. RNA sequencing
of pancreatic circulating tumour cells implicates WNT signalling in
metastasis. Nature. 2012;487:510–3.
31. Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, et al.
RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in
antiandrogen resistance. Science. 2015;349:1351–6.
32. Hodgkinson CL, Morrow CJ, Li Y, Metcalf RL, Rothwell DG, Trapani F, et al.
Tumorigenicity and genetic profiling of circulating tumor cells in small-cell
lung cancer. Nat Med. 2014;20:897–903.
33. Sullivan JP, Nahed BV, Madden MW, Oliveira SM, Springer S, Bhere D, et al.
Brain tumor cells in circulation are enriched for mesenchymal gene
expression. Cancer Discov. 2014;4:1299–309.
34. Luo X, Mitra D, Sullivan RJ, Wittner BS, Kimura AM, Pan S, et al. Isolation and
molecular characterization of circulating melanoma cells. Cell Rep. 2014;7:645–53.
35. Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, et al. Clinical
significance and molecular characteristics of circulating tumor cells and
circulating tumor microemboli in patients with small-cell lung cancer. J Clin
Oncol. 2012;30:525–32.
36. Paoletti C, Li Y, Muñiz MC, Kidwell KM, Aung K, Thomas DG, et al. Significance
of circulating tumor cells in metastatic triple negative breast cancer patients
within a randomized, phase II trial: TBCRC 019. Clin Cancer Res. 2015;21:2771–9.
37. Goodell MA, Nguyen H, Shroyer N. Somatic stem cell heterogeneity:
diversity in the blood, skin and intestinal stem cell compartments. Nat Rev
Mol Cell Biol. 2015;16:299–309.
38. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity,
and uncertainty. Cancer Cell. 2012;21:283–96.
39. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer
stem cells—perspectives on current status and future directions: AACR
Workshop on cancer stem cells. Cancer Res. 2006;66:9339–44.
40. Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving
concept. Nat Rev Cancer. 2012;12:133–43.
41. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating
evidence and unresolved questions. Nat Rev Cancer. 2008;8:755–68.
42. Anderson K, Lutz C, van Delft FW, Bateman CM, Guo Y, Colman SM, et al.
Genetic variegation of clonal architecture and propagating cells in
leukaemia. Nature. 2011;469:356–61.
43. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al.
A cell initiating human acute myeloid leukaemia after transplantation into
SCID mice. Nature. 1994;367:645–8.
44. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al.
Identification of human brain tumour initiating cells. Nature. 2004;432:
396–401.
45. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, et al. Identification
and expansion of the tumorigenic lung cancer stem cell population. Cell
Death Differ. 2008;15:504–14.
46. O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell
capable of initiating tumour growth in immunodeficient mice. Nature. 2007;
445:106–10.
47. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al.
Identification and expansion of human colon-cancer-initiating cells. Nature.
2007;445:111–5.
48. Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM,
et al. CD133 expression defines a tumor initiating cell population in primary
human ovarian cancer. Stem Cells. 2009;27:2875–83.
49. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification
of pancreatic cancer stem cells. Cancer Res. 2007;67:1030–7.
50. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al.
Distinct populations of cancer stem cells determine tumor growth and
metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1:313–23.
51. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF.
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad
Sci U S A. 2013;100:3983–8.
52. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, et al.
Highly purified CD44+ prostate cancer cells from xenograft human tumors
are enriched in tumorigenic and metastatic progenitor cells. Oncogene.
2006;25:1696–708.
53. Kastan MB, Schlaffer E, Russo JE, Colvin OM, Civin CI, Hilton J. Direct
demonstration of elevated aldehyde dehydrogenase in human
hematopoietic progenitor cells. Blood. 1990;75:1947–50.
54. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et
al. ALDH1 is a marker of normal and malignant human mammary stem cells
and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1:555–67.
55. Liu S, Cong Y, Wang D, Sun Y, Deng L, Liu Y, et al. Breast cancer stem cells
transition between epithelial and mesenchymal states reflective of their
normal counterparts. Stem Cell Reports. 2013;2:78–91.
56. Li T, Su Y, Mei Y, Leng Q, Leng B, Liu Z, et al. ALDH1A1 is a marker for
malignant prostate stem cells and predictor of prostate cancer patients’
outcome. Lab Invest. 2010;90:234–44.
57. Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell.
2014;14:275–91.
58. Idowu MO, Kmieciak M, Dumur C, Burton RS, Grimes MM, Powers CN, et al.
CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in
triple-negative invasive breast carcinoma phenotype and are associated
with poor outcome. Hum Pathol. 2012;43(3):364–73.
59. Giatromanolaki A, Sivridis E, Fiska A, Koukourakis MI. The CD44+/CD24-
phenotype relates to ‘triple-negative’ state and unfavorable prognosis in
breast cancer patients. Med Oncol. 2011;28:745–52.
60. Oskarsson T, Batlle E, Massagué J. Metastatic stem cells: sources, niches, and
vital pathways. Cell Stem Cell. 2014;14:306–21.
61. Martelli AM, Evangelisti C, Follo MY, Ramazzotti G, Fini M, Giardino R, et al.
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin
signaling network in cancer stem cells. Curr Med Chem. 2011;18:2715–26.
62. Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, et al. Activation of the
PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for
viability and maintenance. Proc Natl Acad Sci U S A. 2007;104:16158–63.
Gkountela and Aceto Biology Direct  (2016) 11:33 Page 13 of 14
63. Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in
cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14:
736–46.
64. Monteiro J, Gaspar C, Richer W, Franken PF, Sacchetti A, Joosten R, et al.
Cancer stemness in Wnt-driven mammary tumorigenesis. Carcinogenesis.
2014;35:2–13.
65. Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC, et al.
Cancer therapy. Ex vivo culture of circulating breast tumor cells for
individualized testing of drug susceptibility. Science. 2014;345:216–20.
66. Forristal CE, Wright KL, Hanley NA, Oreffo RO, Houghton FD. Hypoxia
inducible factors regulate pluripotency and proliferation in human
embryonic stem cells cultured at reduced oxygen tensions. Reproduction.
2010;139:85–97.
67. Coutu DL, Galipeau J. Roles of FGF signaling in stem cell self-renewal,
senescence and aging. Aging (Albany NY). 2011;3:920–33.
68. Eiselleova L, Matulka K, Kriz V, Kunova M, Schmidtova Z, Neradil J, et al. A
complex role for FGF-2 in self-renewal, survival, and adhesion of human
embryonic stem cells. Stem Cells. 2009;27:1847–57.
69. Smith AG. Embryo-derived stem cells: Of mice and men. Annu Rev Cell Dev
Biol. 2001;17:435–62.
70. Cherepkova MY, Sineva GS, Pospelov VA. Leukemia inhibitory factor (LIF)
withdrawal activates mTOR signaling pathway in mouse embryonic stem
cells through the MEK/ERK/TSC2 pathway. Cell Death Dis. 2016;7:e2050.
71. Tremml G, Singer M, Malavarca R. Culture of mouse embryonic stem cells.
Curr Protoc Stem Cell Biol. 2008;Chapter 1:Unit 1C.4.
72. Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH. Maintenance of
pluripotency in human and mouse embryonic stem cells through activation
of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med.
2004;10:55–63.
73. Sarioglu AF, Aceto N, Kojic N, Donaldson MC, Zeinali M, Hamza B, et al. A
microfluidic device for label-free, physical capture of circulating tumor cell
clusters. Nat Methods. 2015;12:685–91.
74. Duda DG, Duyverman AM, Kohno M, Snuderl M, Steller EJ, Fukumura D, et
al. Malignant cells facilitate lung metastasis by bringing their own soil. Proc
Natl Acad Sci U S A. 2015;107:21677–82.
75. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and
cancer cells induces an epithelial–mesenchymal-like transition and
promotes metastasis. Cancer Cell. 2011;20:576–90.
76. Briegel KJ. Embryonic transcription factors in human breast cancer. IUBMB
Life. 2006;58:123–32.
77. Schumacher D, Strilic B, Sivaraj KK, Wettschureck N, Offermanns S. Platelet-
derived nucleotides promote tumor-cell transendothelial migration and
metastasis via P2Y2 receptor. Cancer Cell. 2013;24:130–7.
78. Qian B, Deng Y, Im JH, Muschel RJ, Zou Y, Li J, Lang RA, et al. A distinct
macrophage population mediates metastatic breast cancer cell
extravasation, establishment and growth. PLoS One. 2009;4:e6562.
79. Koren S, Reavie L, Couto JP, De Silva D, Stadler MB, Roloff T, et al.
PIK3CA(H1047R) induces multipotency and multi-lineage mammary
tumours. Nature. 2015;525:114–8.
80. Van Keymeulen A, Lee MY, Ousset M, Brohée S, Rorive S, Giraddi RR, et al.
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour
heterogeneity. Nature. 2015;525:119–23.
81. Mazel M, Jacot W, Pantel K, Bartkowiak K, Topart D, Cayrefourcq L, Rossille D,
Maudelonde T, Fest T, Alix-Panabières C. Frequent expression of PD-L1 on
circulating breast cancer cells. Mol Oncol. 2015;9:1773–82.
82. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al.
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in
cancer patients. Nature. 2014;515:563–7.
83. Girotti MR, Saturno G, Lorigan P, Marais R. No longer an untreatable disease:
how targeted and immunotherapies have changed the management of
melanoma patients. Mol Oncol. 2014;8:1140–58.
84. Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or
Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373:23–34.
85. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al.
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med.
2015;372:2521–32.
86. Snyder A, Wolchok JD, Chan TA. Genetic basis for clinical response to
CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189–99.
87. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al.
PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Nature. 2014;515:568–71.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Gkountela and Aceto Biology Direct  (2016) 11:33 Page 14 of 14
